May 11th 2005 IPA Conference Pompe’s disease Nantes, France. “Emerging therapies for Pompe diseaseA rare genetic disease in which the body cannot properly break down glycogen, leading to buildup tha... More” Dr. Ans van der Ploeg, Erasmus

CAMBRIDGE, Mass.—Genzyme Corp. (Nasdaq: GENZ) announced today that it has completed a planned analysis of interim data from its pivotal

CAMBRIDGE, MA—Genzyme Corp. (Nasdaq: GENZ) announced today that the European Medicines Agency (EMEA) has accepted its marketing authorization application for

On 9th and 10th October, the AGSD (UK) held its annual patient conference. This year we were more ambitious than

Medical experts and patients are invited to attend the International Pompe Conference 2003. The goal of the conference is to

Genzyme General (Nasdaq: GENZ), a division of Genzyme Corp., announced today that it has treated the first patient in a

CAMBRIDGE, Mass – Genzyme General (Nasdaq: GENZ), a division of Genzyme Corp., announced today that it has begun enrolment in

An update by Genzyme regarding treatment for Pompe diseaseA rare genetic disease in which the body cannot properly break down glycogen, leading to buildup tha... More. Q: What is the status of the Pompe program? Genzyme has

IBaarn, October 2nd 2002 Dear IPA members, Herewith I would like to inform you about the IPA/Genzyme telephone conference of

In July 2002, Genzyme began the transition of the nine transgenic (rabbit derived enzymeA protein that helps the body carry out chemical reactions. More) patients to the CHO derived product.